U.S. markets closed

Landos Biopharma, Inc. (LABP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.93-0.23 (-2.26%)
At close: 4:00PM EDT

Landos Biopharma, Inc.

1800 Kraft Drive
Suite 216
Blacksburg, VA 24060
United States
540 218 2232

Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Dr. Josep Bassaganya-Riera DVM, Ph.D.Chairman, Pres & CEO741.77kN/A1975
Ms. Jyoti Chauhan M.S.Exec. VP of Operations & Regulatory Affairs281.42kN/A1989
Dr. Raquel Hontecillas DVM, Ph.D.Chief Scientific Officer228.76kN/A1972
Ms. Jennifer Collette CPAVP of Fin. & ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Corporate Governance

Landos Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.